All In Biotech

Drug Trial Radar · NCT05750355

Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

A Single-dose-oral, Ascending-Dose, Single-Center,Randomized, Double-Blind, Placebo-Parallel-controlled Study for the Evaluation of the Effect of TPN171H Tablets on the QT/QTc Intervals in Adult Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Oct 10, 2022

Primary completion

Dec 7, 2022

Study completion Dec 7, 2022

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Mar 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-dose orally administered, dose-escalation, single-center, randomized, double-blind, placebo-parallel controlled clinical study evaluating the effect of TPN171H tablets on QT/QTc interval in healthy subjects.The main objective was to evaluate the effect of TPN171H tablets on QT/QTc interval in healthy Chinese subjects after a single oral administration.

Conditions

  • Healthy Subjects

Interventions

  • TPN171H 10 mg GroupDrug

    6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.

  • TPN171H 30 mg GroupDrug

    6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.

  • TPN171H 40 mg GroupDrug

    6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.

  • TPN171H 50 mg GroupDrug

    6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QT Interval Corrected Using Fridericia's FormulaTime frame: From Day 1 to Day3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.